Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

33.91
-0.3100-0.91%
Pre-market: 33.50-0.4100-1.21%08:25 EST
Volume:4.78M
Turnover:161.77M
Market Cap:39.51B
PE:28.02
High:34.92
Open:33.96
Low:33.63
Close:34.22
52wk High:37.35
52wk Low:12.47
Shares:1.17B
Float Shares:1.14B
Volume Ratio:0.64
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.21
EPS(LYR):1.21
ROE:20.79%
ROA:6.17%
PB:4.99
PE(LYR):28.02

Loading ...

Has Teva (TEVA) Run Too Far After Its 102% One-Year Share Price Surge?

Simply Wall St.
·
2 hours ago

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application

Benzinga
·
Yesterday

Teva Pharmaceutical Says FDA Accepts New Drug Application for Olanzapine in Schizophrenia Treatment

MT Newswires Live
·
Feb 21

FDA accepts Teva NDA for olanzapine extended-release injectable suspension

TIPRANKS
·
Feb 21

BRIEF-Corcept Says US Court Rules Teva's Generic Korlym Does Not Infringe Corcept Patents

Reuters
·
Feb 20

Corcept Therapeutics Inc - Ruling Affirms December 2023 Verdict by Federal District Court

THOMSON REUTERS
·
Feb 20

Corcept Therapeutics Inc - Considering Judicial Review of Court Decision

THOMSON REUTERS
·
Feb 20

Corcept Provides Update on Patent Dispute With Teva Pharmaceuticals

THOMSON REUTERS
·
Feb 20

Truist Financial Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Feb 19

Teva Pharmaceuticals Is Maintained at Buy by Truist Securities

Dow Jones
·
Feb 18

BRIEF-Viking Global Reports Share Stake In Amazon, Raises In Boeing & T-Mobile, Dissolves In BlackRock

Reuters
·
Feb 18

Truist Securities Adjusts Teva Pharmaceutical Industries Price Target to $42 From $38, Maintains Buy Rating

MT Newswires Live
·
Feb 18

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Benzinga_recent_news
·
Feb 17

Teva and Sanofi’s duvakitug Phase 2b data shows efficacy in colitis and Crohn’s

TIPRANKS
·
Feb 17

BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease

Reuters
·
Feb 17

Teva: Duvakitug Was Well Tolerated and Safety Was Consistent With Induction Study

THOMSON REUTERS
·
Feb 17

Teva and Sanofi’s Duvakitug Phase 2B Maintenance Data Demonstrated Clinically Meaningful Durable Efficacy in Ulcerative Colitis and Crohn’s Disease

THOMSON REUTERS
·
Feb 17

Teva (TEVA) Is Down 5.2% After Returning To Profitability On Innovation-Led Revenue Shift – What’s Changed

Simply Wall St.
·
Feb 12

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Momentum And Biosimilar Growth Hopes

Simply Wall St.
·
Feb 10

Teva Pharmaceuticals Is Maintained at Buy by Goldman Sachs

Dow Jones
·
Feb 10